Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

López-Riera, Mireia; Conde, Isabel; Quintás, Guillermo; Pedrola, Laia; Zaragoza, Ángela; Pérez‐Rojas, Judith; Salcedo, Mario; Benlloch, Salvador; Castell, José V.; Jover, Ramiro

doi:10.1038/s41598-018-28854-4

Cited by 61 publications

(74 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 For mi-RNA-122, the AUC was 0.831 (p< 0.0001) with 75.0% sensitivity and 82.35% specificity. López-Riera et al 45 Figure 2 (A) The ROC curve of mi-RNA-122 and ALT levels among patients with NAFLD disease. (B) The ROC curve of mi-RNA-99a and ALT levels among patients with NASH.…”

Section: Discussionmentioning

confidence: 99%

“…Hendy reported an AUC of 0.812 for mi-RNA-122 followed by 0.76 for mi-RNA-34a for NAFLD diagnosis. 45 The mi-RNA-99a downregulation is a good predictor for NASH development, it can discriminate NASH from SS with AUR 0.91 followed by mi-RNA-34a upregulation with AUR 0.84, then mi-RNA-122 with AUR 0.81. The last predictor for NASH is ALT elevation with AUR 0.66, suggesting the mi-RNA-99a is an excellent predictor for NASH development with a high sensitivity (94%) compared to ALT level, which gives a low sensitivity (73%).…”

Section: Dovepressmentioning

confidence: 96%

See 1 more Smart Citation

<p>The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases</p>

Hendy

Rabie

Fouly

et al. 2019

DMSO

View full text Add to dashboard Cite

Background: It remains essential for patient safety to develop non-invasive diagnostic tools to diagnose non-alcoholic fatty liver rather than invasive techniques. Aim: Our case-control study was to address the value of circulating miRNAs as a potential non-invasive biomarker for the diagnosis of non-alcoholic fatty acid diseases (NAFLD) and monitoring of disease progression. Methods: Routine clinical assessment, laboratory tests, anthropometric study, and liver biopsy results reported for 210 patients with NAFLD (124 patients of simple steatosis (SS) and 86 of non-alcoholic steatohepatitis (NASH)). Apparently matched for age and gender, healthy participants (n= 90) were enrolled as a control group. Serum samples were tested for micro-RNAs (−122, −34a and −99a) by quantitative-PCR. Results: By histopathology, 124 of the NAFLD group were of SS and 86 patients were of NASH. Compared with the control subjects, both mi-RNA-122 and −34a levels were increased in NAFLD (p< 001) and at a cutoff = 1.261, mi-RNA-122 had 92% sensitivity, 85% specificity to differentiate NAFLD from healthy controls, while mi-RNA-99a were significantly decreased in NAFLD patients with an observed decrease in disease severity, and at a cutoff = 0.46, miRNA-99a had 94% sensitivity and 96% specificity to discriminate SS from NASH. Conclusion: The integration of a circulating mi-RNA panel to diagnose NAFLD cases and to discriminate between SS and NASH. Large-scale study is still needed to verify the other mi-RNA profiles and their role in NAFLD pathogenesis and targeting therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Dovepressmentioning

confidence: 96%

<p>The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases</p>

Hendy

Rabie

Fouly

et al. 2019

DMSO

View full text Add to dashboard Cite

show abstract

“…Serum microRNAs are little in content and short in length. [43][44][45][46] In addition, microRNAs are pochissimo in serum and below the lower limit of the spectrophotometer. 41 In this study, a special microRNA adsorption column was used for RNA extraction.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Yin

Yang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cervical cancer is the third leading cause of female death in the world. Serum microRNAs (miRNAs) are currently considered to be valuable as noninvasive cancer biomarkers, but their role in the prognosis of cervical cancer has not been elucidated. We aimed to find serum miRNAs that can be used as prognostic factors for cervical cancer. A traumatic pathological biopsy is the only reliable method for determining the severity of cervical cancer currently. Thus, noninvasive diagnostic markers are needed. The serological expression of candidate miRNAs were measured in 90 participants, including 60 patients with cervical cancer and 50 patients with cervical intraepithelial neoplasia. Two patients with cervical cancer were excluded from the study because of lack of data. miRNAs were evaluated by quantitative reverse transcription polymerase chain reaction. miR‐143/−4636 appeared specific for cervical cancer compared with cervical intraepithelial neoplasia (P < .001). The classification performance of validated miRNAs for cervical cancer [Area under the receiver operating characteristic curve (AUC) = 0.942] was better than that reached by squamous cell carcinoma antigen (SCC‐Ag; AUC = 0.727). Poor‐differentiation group has lower miR‐143/−4636 levels in serum (P < .05). miR‐4636 level was correlated gross tumor volume and the depth of invasion (P < .0001). In our study, we found a combination of miR‐143 and miR‐4636 that is independently and strongly associated with cervical cancer prognosis and can be used as a clinically prognostic factor.

show abstract

“…During the preliminary screening process (title and abstract screening), we eliminated irrelevant articles (n = 988) and experimental studies (n = 1967). During the second screening process (full-text review), we included nine articles that met the eligibility criteria [20][21][22][23][24][25][26][27][28]. A ow diagram of the literature selection process is presented in Fig 1. The meta-analysis was conducted on 27 trials included in nine articles.…”

Section: Literature Retrieval Characteristics and Quality Assessmentmentioning

confidence: 99%

Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis.

Xin

Zhan

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

1. Background: Nonalcoholic steatohepatitis (NASH) is a key turning point during the progression of nonalcoholic fatty liver disease (NAFLD). Recent studies have shown that serum miRNA tests may be effective in the diagnosis of NAFLD. We conducted a meta-analysis to assess the evidence for the diagnostic efficacy of serum miRNAs in patients with NAFLD and its subtype, NASH, in particular. 2. Methods: After a systematic review, sensitivity, specificity, and area under the receiver operating characteristics curve (AUROC) were pooled to determine the efficacy of serum miRNA test for the diagnosis of NAFLD and NASH. Clinical utility was evaluated by Fagan’s nomogram and likelihood ratio scattergram. Heterogeneity was evaluated by subgroup analysis and meta-regression. Publication bias was detected by Deeks’ funnel plot. 3. Results: We included 27 trials containing 1775 NAFLD patients (including simple steatosis and NASH) and 586 NASH patients. For NAFLD vs NASH, the pooled sensitivity, specificity, and AUROC were (0.71 vs. 0.74), (0.76 vs. 0.85) and (0.80 vs. 0.86), respectively. Serum miRNA had high accuracy for distinguishing NASH from simple steatosis, with an AUROC of 0.91. Among the most commonly studied serum miRNAs , miRNA-34a showed moderate diagnostic accuracy for NAFLD and the lowest heterogeneity (sensitivity I 2 = 5.73%, specificity I 2 = 33.16%, AUROC = 0.85). According to subgroup analysis and meta-regression, a lower BMI ( < 30 kg/m 2 ) might be a crucial source of heterogeneity. 4.Conclusions: As a novel non-invasive method, serum miRNA test exhibited robust diagnostic efficacy for NASH. Among these well-studied miRNAs, miRNA-34a was more available for diagnosis. Diagnosis of NAFLD by serum miRNA is more likely to be accurate in patients with BMI ≥ 30kg/m 2 .

show abstract

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

Cited by 61 publications

References 46 publications

<p>The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases</p>

<p>The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases</p>

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis.

Contact Info

Product

Resources

About